BRPI0819598A2 - anticorpos para o antígeno pcrv da pseudomonas aeruginosa - Google Patents
anticorpos para o antígeno pcrv da pseudomonas aeruginosaInfo
- Publication number
- BRPI0819598A2 BRPI0819598A2 BRPI0819598A BRPI0819598A BRPI0819598A2 BR PI0819598 A2 BRPI0819598 A2 BR PI0819598A2 BR PI0819598 A BRPI0819598 A BR PI0819598A BR PI0819598 A BRPI0819598 A BR PI0819598A BR PI0819598 A2 BRPI0819598 A2 BR PI0819598A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- pseudomonas aeruginosa
- aeruginosa pcrv
- pcrv antigen
- antigen
- Prior art date
Links
- 241000589517 Pseudomonas aeruginosa Species 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99167907P | 2007-11-30 | 2007-11-30 | |
| PCT/US2008/085196 WO2009073631A2 (en) | 2007-11-30 | 2008-12-01 | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0819598A2 true BRPI0819598A2 (pt) | 2017-05-09 |
Family
ID=40527381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0819598A BRPI0819598A2 (pt) | 2007-11-30 | 2008-12-01 | anticorpos para o antígeno pcrv da pseudomonas aeruginosa |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8044181B2 (enExample) |
| EP (1) | EP2220117A2 (enExample) |
| JP (1) | JP5781765B2 (enExample) |
| KR (1) | KR20100097719A (enExample) |
| CN (1) | CN101910197B (enExample) |
| AU (1) | AU2008333985B2 (enExample) |
| BR (1) | BRPI0819598A2 (enExample) |
| CA (1) | CA2706732A1 (enExample) |
| EA (1) | EA201000903A1 (enExample) |
| IL (1) | IL206036A0 (enExample) |
| MX (1) | MX2010005871A (enExample) |
| NZ (1) | NZ586357A (enExample) |
| SG (1) | SG186017A1 (enExample) |
| WO (1) | WO2009073631A2 (enExample) |
| ZA (1) | ZA201003852B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| JP2008507294A (ja) | 2004-07-26 | 2008-03-13 | ダウ グローバル テクノロジーズ インコーポレイティド | 菌株遺伝子操作による改善されたタンパク質発現のための方法 |
| EP2615172A1 (en) * | 2007-04-27 | 2013-07-17 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9580719B2 (en) * | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| KR101259239B1 (ko) | 2008-01-10 | 2013-04-29 | 시오노기세야쿠 가부시키가이샤 | ＰｃｒＶ에 대한 항체 |
| CA2751433A1 (en) * | 2009-02-04 | 2010-08-12 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
| PT2407537E (pt) * | 2009-03-11 | 2015-02-17 | Shionogi & Co | Anticorpo pcrv humanizado com atividade anti-pseudomonal |
| JP2013515079A (ja) * | 2009-12-22 | 2013-05-02 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法 |
| WO2012012571A1 (en) | 2010-07-21 | 2012-01-26 | Hans Zassenhaus | Biolayer interferometry measurement of biological targets |
| KR102111171B1 (ko) * | 2011-06-10 | 2020-05-14 | 메디뮨 엘엘씨 | 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도 |
| SMT202000542T1 (it) | 2011-11-07 | 2020-11-10 | Medimmune Ltd | Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas |
| JP6415987B2 (ja) | 2012-03-02 | 2018-10-31 | アブリンクス エン．ヴェー． | シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体 |
| EP2917236A2 (en) * | 2012-11-06 | 2015-09-16 | MedImmune, LLC | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
| MX2017014002A (es) | 2015-05-01 | 2018-08-01 | Inhibrx Lp | Moléculas de direccionamiento del sistema de secreción tipo iii . |
| HUE051896T2 (hu) | 2015-07-16 | 2021-03-29 | Inhibrx Inc | Multivalens és multispecifikus DR5-kötõ fúziós fehérjék |
| CN110072554A (zh) * | 2016-05-05 | 2019-07-30 | 宾夕法尼亚大学理事会 | 用于抗铜绿假单胞菌的dna抗体构建体 |
| CA3108071A1 (en) * | 2018-08-01 | 2020-02-06 | Cephalon, Inc. | Anti-cxcr2 antibodies and uses thereof |
| PH12021552903A1 (en) * | 2019-06-11 | 2022-04-04 | Regeneron Pharma | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof |
| CN114072145B (zh) * | 2020-06-01 | 2024-06-11 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别假单胞菌pcrv的抗体及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US225552A (en) * | 1880-03-16 | Disintegrating-mill | ||
| US108565A (en) * | 1870-10-25 | Improvement in snow-plows | ||
| US134098A (en) * | 1872-12-17 | Improvement in gage-cocks | ||
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5219998A (en) * | 1990-06-04 | 1993-06-15 | Levin Robert H | Yeast-derived epidermal growth factor |
| GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
| JP2000516452A (ja) | 1996-07-16 | 2000-12-12 | プリュックテュン，アンドレアス | 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント |
| US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| AU3580800A (en) * | 1998-11-25 | 2000-06-26 | Mcw Research Foundation, Inc. | Method of and compositions for immunization with the (pseudomonas) v antigen |
| DE19918418C1 (de) * | 1999-04-23 | 2000-10-19 | Siegfried Mueller | Pflanzvorrichtung mit Halterung |
| AU2001238677A1 (en) | 2000-02-28 | 2001-09-12 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| JP4355786B2 (ja) * | 2001-01-26 | 2009-11-04 | エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド | シュードモナスｖ抗原を用いる免疫化のための方法および組成物 |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| EP1479695B1 (en) * | 2003-05-14 | 2010-02-17 | Kenta Biotech AG | Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa |
| EP1761561B1 (en) * | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| AU2005306502B2 (en) | 2004-11-16 | 2012-11-15 | Humanigen, Inc. | Immunoglobulin variable region cassette exchange |
| CA2606576A1 (en) | 2005-05-20 | 2006-11-23 | Lonza Biologics Plc. | High-level expression of recombinant antibody in a mammalian host cell |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| US20090317329A2 (en) | 2005-07-05 | 2009-12-24 | Baker Idi Heart & Diabetes Institute Holdings Limited | Anticoagulation agent and uses thereof |
| CA2635445A1 (en) | 2006-02-22 | 2007-08-30 | University Of Zurich | Methods for treating autoimmune or demyelinating diseases |
| AU2007254942B2 (en) | 2006-06-02 | 2011-10-27 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
| KR101351208B1 (ko) | 2006-06-21 | 2014-01-14 | 온코세라피 사이언스 가부시키가이샤 | Ｆｚｄ10에 대한 종양-표적화 모노클로날 항체 및 이의 용도 |
-
2008
- 2008-12-01 EA EA201000903A patent/EA201000903A1/ru unknown
- 2008-12-01 BR BRPI0819598A patent/BRPI0819598A2/pt not_active IP Right Cessation
- 2008-12-01 WO PCT/US2008/085196 patent/WO2009073631A2/en not_active Ceased
- 2008-12-01 SG SG2012085239A patent/SG186017A1/en unknown
- 2008-12-01 NZ NZ586357A patent/NZ586357A/xx not_active IP Right Cessation
- 2008-12-01 CN CN200880124705.7A patent/CN101910197B/zh not_active Expired - Fee Related
- 2008-12-01 JP JP2010536228A patent/JP5781765B2/ja not_active Expired - Fee Related
- 2008-12-01 EP EP08856948A patent/EP2220117A2/en not_active Ceased
- 2008-12-01 US US12/325,806 patent/US8044181B2/en not_active Expired - Fee Related
- 2008-12-01 AU AU2008333985A patent/AU2008333985B2/en not_active Ceased
- 2008-12-01 MX MX2010005871A patent/MX2010005871A/es active IP Right Grant
- 2008-12-01 CA CA2706732A patent/CA2706732A1/en active Pending
- 2008-12-01 KR KR1020107014345A patent/KR20100097719A/ko not_active Ceased
-
2010
- 2010-05-27 IL IL206036A patent/IL206036A0/en unknown
- 2010-05-28 ZA ZA2010/03852A patent/ZA201003852B/en unknown
-
2011
- 2011-10-11 US US13/271,146 patent/US8877191B2/en not_active Expired - Fee Related
-
2014
- 2014-10-08 US US14/509,437 patent/US20150030614A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100097719A (ko) | 2010-09-03 |
| EP2220117A2 (en) | 2010-08-25 |
| JP2011505381A (ja) | 2011-02-24 |
| US8044181B2 (en) | 2011-10-25 |
| NZ586357A (en) | 2012-10-26 |
| CN101910197A (zh) | 2010-12-08 |
| IL206036A0 (en) | 2010-11-30 |
| AU2008333985B2 (en) | 2015-02-05 |
| US20120020986A1 (en) | 2012-01-26 |
| WO2009073631A3 (en) | 2009-09-24 |
| US8877191B2 (en) | 2014-11-04 |
| CN101910197B (zh) | 2014-09-24 |
| EA201000903A1 (ru) | 2011-02-28 |
| WO2009073631A2 (en) | 2009-06-11 |
| JP5781765B2 (ja) | 2015-09-24 |
| AU2008333985A1 (en) | 2009-06-11 |
| CA2706732A1 (en) | 2009-06-11 |
| SG186017A1 (en) | 2012-12-28 |
| MX2010005871A (es) | 2010-06-09 |
| US20090191186A1 (en) | 2009-07-30 |
| ZA201003852B (en) | 2014-11-26 |
| US20150030614A1 (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0819598A2 (pt) | anticorpos para o antígeno pcrv da pseudomonas aeruginosa | |
| CY2021027I1 (el) | Σκευασματα αντισωματων anti-cd20 | |
| CY2019004I2 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
| DK2234600T3 (da) | Antistofformulering | |
| BRPI0814252A2 (pt) | Formulações de anticorpo | |
| PL3059246T3 (pl) | Zmodyfikowany region stały przeciwciała | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| SMT201600288B (it) | SPECIFICI ANTICORPI IgE | |
| DK3072906T3 (da) | Antistofformulering | |
| EP2358392A4 (en) | ANTIBODY FORMULATION | |
| EP2281845A4 (en) | STABLE POLYVALENT ANTIBODY | |
| NO344963B1 (no) | Humanisert antistoff | |
| DK2131860T3 (da) | Anti-sclerostin-antistoffer | |
| EP2211903A4 (en) | CLL-1 ANTIBODY | |
| PT2195026E (pt) | Anticorpos anti-esclerostina | |
| BRPI0917204A2 (pt) | variantes estruturais de anticorpos para melhores características terapêuticas | |
| BRPI0821777A2 (pt) | Anticorpos biespecíficos bivalentes | |
| EP2324359A4 (en) | MONOCLONAL ANTIBODY STRO-4 | |
| BRPI0807991A2 (pt) | Anticorpos anti-il-23r elaborados. | |
| HUE050985T2 (hu) | Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák | |
| BRPI0919975A2 (pt) | imunoensaio para galectina-3 | |
| BRPI0817427A2 (pt) | Anticorpo anti-bst2 | |
| CR10705A (es) | Anticuerpos para linfotoxina-alfa | |
| EP2172483A4 (en) | ANTI-MUC17 ANTIBODY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |